Mediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures but also from more European VCs like by Gimv together with Pureos.
Biontech leaves; what does Germany do?
BackgroundIn soccer, such a transfer would raise tempers: A superstar leaves his team because he no longer trusts it to succeed. A warning sign, a headline event, fodder for weeks of debate in the media. Something similar has just happened to the biotech industry, but things remain strangely quiet in the fan block of Germanys top research – whispers at best, just whispers, but no outcry anywhere.
Biomanufacturing: Step up and speak up
OpinionIn a world where biotechnology has been enabling products and processes for decades, it’s time to step out from behind the technology and claim the resulting products and their value in our everyday life. It needs higher visibility and recognition of impact, moving beyond its ‘enabling’ brand which forever makes it sound like the benefits are just around the corner, rather than the existing significant economic and industrial impact.
European VCs join US$105m financing of US Mediar Thx
Latest NewsMediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures but also from more European VCs like by Gimv together with Pureos.
Neurodegenerative disorders are being fought with €28m
Latest NewsDanish Teitur Trophics ApS announced the completion of a €28m Series A funding to progress drugs against several neurodegenerative diseases.
Pfizer-Seagen: Acquisition in the works
Latest NewsPfizer strengthens its oncology portfolio by acquiring Seagen, the biotech specialist in antibody-drug conjugates technology.
Iktos SA raises €15.5m in Series A financing
Latest NewsParis-based AI-inspired drug discovery specialist Iktos SA has closed a €15.5m financing to expand its platform and kick-start the new CRO Iktos Robotics.
Collaboration to fight cancer
Latest NewsThe charity Cancer Research UK and UCB SA collaborate on the development of two potential cures for cancer.
Noema Pharma AG closes Series B financing
Latest NewsNoema Pharma AG receives €104m in oversubscribed Series B financing round to advance its central nervous system pipeline.
Bayer AG presents successor für CEO Baumann
AppointmentsThe Supervisory Board of Bayer AG has appointed Roche Pharmaceuticals CEO Bill Anderson (56) as new Chairman of the Management Board of Bayer AG with effect from 1 June 2023.
Oculis lists at Nasdaq through SPAC merger
Latest NewsThe eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp.